Expression of immunostimulator and immunoinhibitor molecules [34], other than PD-L1 and PD-1, respectively, were generally increased in BRCA1-deficient breast cancers, but not in BRCA2-deficient breast cancers, compared to BRCA-proficient breast cancers. This evidence concerns the gene CD274 and breast cancer.